Last reviewed · How we verify

Low-dose anrikefon — Competitive Intelligence Brief

Low-dose anrikefon (Low-dose anrikefon) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon-alpha analog. Area: Immunology, Virology.

marketed Interferon-alpha analog Interferon-alpha receptor (IFNAR) Immunology, Virology Small molecule Live · refreshed every 30 min

Target snapshot

Low-dose anrikefon (Low-dose anrikefon) — Peking University First Hospital. Anrikefon is an interferon-alpha derivative that enhances innate immune responses and has antiviral and antiproliferative properties.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Low-dose anrikefon TARGET Low-dose anrikefon Peking University First Hospital marketed Interferon-alpha analog Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon-alpha analog class)

  1. Peking University First Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose anrikefon — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-anrikefon. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: